Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
Dong Hoon Shin(National Cancer Center), Sang Soo Kim(National Cancer Center)
Cited by 18
Related Papers
Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal Antibody
|Molecular Cancer Therapeutics|2011|43
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors
|Experimental & Molecular Medicine|2018|15
Inhibition of Estrogen Signaling Reduces the Incidence of <i>BRCA1</i>-associated Mammary Tumor Formation
|International Journal of Biological Sciences|2018|12